Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

An AI model has been developed to predict the degree of height growth after treatment with growth hormone drugs. LG Chem said ...

OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that three of its research abstracts have been accepted for poster ...

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and ...

Verismo Therapeutics, a clinical-stage CAR T company pioneering the KIR-CAR platform, today provided additional details on ...

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Preclinical Psoriasis Data Presented at SID Annual Meeting On May 16, 2025, FibroBiologics, Inc. (NASDAQ:FBLG) announced a poster presentation ...

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small ...

From scholarly lectures to TED-style talks, from academic posters to interactive workshops, we engage with audiences ranging from field experts to the general public. This multi-faceted approach to ...

were selected for a poster presentation at the European Hematology Association (EHA) 2025 Congress, taking place June 12–15 in Milan, Italy. The presentation will highlight emerging safety ...

CHICAGO — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the presentation of six posters, including one ...